SUVEN360.00

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹9,494 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUVEN
FY26
VIMTALABS
FY24
TAKE
FY26
Peer
Median
Valuation — at last close
P/E34.49×22.68×28.59×
P/B16.05×4.43×7.99×6.21× +158%
EV/EBITDA-33.34×16.38×-129.54×-56.58× +41%
Market Cap₹9,494 Cr₹1,416 Cr₹248 Cr₹832 Cr +1041%
Growth
Revenue CAGR 3Y-19.30%14.74%-34.07%-9.66% -100%
Revenue CAGR 5Y-12.00%8.40%-41.25%-16.43% +27%
Net Income CAGR 3Y24.20%24.20%
Revenue YoY (latest Q)91.02%10.09%73981.22%36995.65% -100%
Net Income YoY (latest Q)-147.71%112.16%216.76%164.46% -190%
Profitability
EBITDA Margin-3998.80%27.27%-3.53%11.87% -33788%
Net Income Margin-3884.13%12.89%20.02%16.45% -23705%
Return on Common Equity-46.73%12.83%35.00%23.91% -295%
Return on Capital Employed-48.90%15.20%-6.20%4.50% -1187%
Return on Assets-44.27%10.25%29.94%20.09% -320%
Credit & Quality
Total Debt/Equity0.00×0.06×0.00×0.03× -100%
Interest Coverage-1838.51×24.79×-5.51×9.64× -19172%
Scale — latest FY
Revenue / Total Income₹7.1 Cr₹318 Cr₹54.2 Cr₹186 Cr -96%
Net Income−₹276 Cr₹41 Cr₹10.8 Cr₹25.9 Cr -1166%
Total Assets₹624 Cr₹400 Cr₹36.2 Cr₹218 Cr +186%
EPS₹-12.13₹18.51₹0.74₹9.63 -226%
Book Value per Share₹22.43₹144.2₹2.1₹73.15 -69%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.